SUMMARY
Despite the success achieved in the prevention and treatment of acute respiratory viral infections their annual prevalence exceeds the prevalence of the rest of the infectious diseases, and their portion in the overall structure of the infectious diseases reaches 90-95 %. Therefore, the development of new approaches to the treatment of acute respiratory viral infections and prevention of their complications remain a current urgent problem in practical medicine and pharmacy. Imupret® (“Bionori?a”, Germany) contains BNO 1030 extract standardized by biologically active substances, obtained using a unique phytoneering technology from seven plant components, such as marshmallow root, chamomile flowers, horsetail grass, walnut leaf, yarrow grass, bark oak and dandelion herb; it is actively used to treat diseases of the upper respiratory tract (tonsillitis, pharyngitis, laryngitis), and prevent complications and relapses in acute respiratory viral infections. An important component of the pharmacodynamics of BNO 1030 is its antiviral and antibacterial effect. For many years, the European and domestic scientists have accumulated a solid database of scientific data that describe the complex positive effect of the active substance BNO 1030 on the immune system. The high scientific potential that underlies the concept of phytoneering allows us to create drugs not only of high quality, but also with high efficiency comparable to synthetic drugs of the similar action (comprehensive preclinical and clinical studies on the mechanisms of action, pharmacological effects, confirmation of efficacy and tolerability). At the same time, a scientifically based complex of various biologically active substances in a definite ratio provides the presence of a number of multidirectional effects (pleiotropy), which affect various functions of the body, including certain links of pathogenesis.Conclusions. Imupret® is the drug of choice in the treatment of acute respiratory viral infections, for the prevention of their complications, as well as in the combination therapy of chronic upper respiratory tract infections. Its effectiveness in the treatment of acute respiratory viral infections and prevention of their complications has been substantiated by the pathogenetic mechanisms of the pharmacological action and proven by a number of experimental studies. The effectiveness and high safety of Imupret® have been confirmed by many years of the practical experience in wide medical practice, as well as a sufficient number of clinical trials of various phases and designs.